1
|
Husian S, Jeyaraman P, Gupta SK, Rai R, Pathak S, Dayal N, Naithani R. Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization. South Asian J Cancer 2021; 10:172-174. [PMID: 34938680 PMCID: PMC8687862 DOI: 10.1055/s-0041-1729446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Methods
This is a retrospective study. G-CSF was administered in the dose of 10 μg/kg subcutaneous as a single dose for 4 days. On day 5, peripheral blood stem cell (PBSC) apheresis was performed using Haemonetics MCS plus or COBE Spectra apheresis machine through a double-lumen central venous catheter. Primary outcome parameters were the total number of CD34+ HSCs/kg of recipient weight mobilized in peripheral blood and the number of days required for neutrophil and platelets engraftment, respectively.
Objective
We compared the effectiveness and safety of innovator filgrastim versus generic filgrastim in patients who underwent hematopoietic stem cell transplantation (HSCT).
Results
A total of 91 stem cell mobilizations was analyzed. There were 58 normal healthy donors for allogeneic HSCT and 33 patients for autologous HSCT. There was no statistically significant difference among groups in terms of total collected CD34+ cells value (
p
= 0.609). The mean time to neutrophil engraftment was 13.7 days in the innovator group and 13.2 days in the Grafeel group (
p
= 0.518). The mean time to platelet engraftment was 16.2 days in the innovator group and 14.8 days in the generic group (
p
= 0.435). The patient who received generic filgrastim had more febrile episodes during the course of transplantation (
p
= 0.020).
Conclusion
Generic filgrastim was found to be comparable to original filgrastim for peripheral blood stem cell mobilization in normal healthy donors for allogeneic HSCT and patients for autologous HSCT.
Collapse
Affiliation(s)
- Sadik Husian
- Department of Pharmacology, Pharmaceutical Sciences and Research University, New Delhi, India
| | - Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplant, Saket, New Delhi, India
| | - S K Gupta
- Department of Pharmacology, Pharmaceutical Sciences and Research University, New Delhi, India
| | - Reeta Rai
- Division of Transfusion Medicine, Department of Lab Medicine Transfusion Medicine, Max Super Specialty Hospital, Saket, New Delhi, India
| | - Sangeeta Pathak
- Division of Transfusion Medicine, Department of Lab Medicine Transfusion Medicine, Max Super Specialty Hospital, Saket, New Delhi, India
| | - Nitin Dayal
- Department of Lab Medicine, Max Super Specialty Hospital, Saket, New Delhi, India
| | - Rahul Naithani
- Division of Hematology and Bone Marrow Transplant, Saket, New Delhi, India
| |
Collapse
|
2
|
Agrawal N, Singh R, Sharma SK, Naithani R, Bhargava R, Choudhary D, Jeyaraman P, Bansal S, Doval D, Khandelwal V, Bansal N, Ahmed R, Bhurani D. Outcomes of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: Multicenter Retrospective Analysis. Indian J Hematol Blood Transfus 2021; 38:388-393. [PMID: 34305341 PMCID: PMC8284695 DOI: 10.1007/s12288-021-01472-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 07/05/2021] [Indexed: 01/08/2023] Open
Abstract
COVID-19, caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 9, 2020. Hematopoietic stem-cell transplantation (HSCT) recipients may be highly susceptible to infection and related pulmonary complications due to nascent immune systems or organ damage from treatment-related toxicities. Poor outcomes in such group of patients were linked to older age, steroid therapy at the time of COVID-19 infection, and COVID-19 infection within a year of HSCT. We studied a cohort of 28 hematopoietic stem cell transplant recipients (male 17, M:F ratio of 1.5) with COVID-19 infection from 1st June 2020, through 31st December 2020 for outcome. Fever was the most common symptom at the time of presentation in 22 (78.5%) patients. Mortality rate at Day 28 and Day 42 was found to be 4/28 (14.3%) and 7/28 (25%) respectively. Patients within one year of HSCT and severe infection had higher day 28 mortality (with p values = 0.038)". There was no relation of mortality with type of transplant.
Collapse
Affiliation(s)
- Narendra Agrawal
- Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Sector 5, Rohini, Delhi, 110085 India
| | - Reema Singh
- Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Sector 5, Rohini, Delhi, 110085 India
| | | | | | | | | | | | | | | | | | - Nitin Bansal
- Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Sector 5, Rohini, Delhi, 110085 India
| | - Rayaz Ahmed
- Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Sector 5, Rohini, Delhi, 110085 India
| | - Dinesh Bhurani
- Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Sector 5, Rohini, Delhi, 110085 India
| |
Collapse
|
3
|
Jeyaraman P, Agrawal N, Bhargava R, Bansal D, Ahmed R, Bhurani D, Bansal S, Rastogi N, Borah P, Naithani R. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. Transfus Apher Sci 2021; 60:103075. [PMID: 33574010 PMCID: PMC7857080 DOI: 10.1016/j.transci.2021.103075] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 01/27/2021] [Accepted: 02/01/2021] [Indexed: 02/06/2023]
Abstract
BACKGROUND Data on convalescent plasma therapy (CPT) in patients of hematological malignancies with severe Covid-19 is scarce. OBJECTIVE To study 14-day mortality in patients who received CPT. PATIENTS & METHODS Retrospective multicentre observational study conducted in 4 centres treating haematological malignancies across Delhi-national capital region. Total 33 haematological malignancies patients with severe Covid-19 who received CPT were analysed. RESULTS The median age of the study cohort was 62 years (18-80 years). Twenty one percent patients had 1 comorbidity, 18 % had 2 comorbidities and 6% patients had 3 and 5 comorbidities each. Twenty four patients were on active therapy. Sixty nine percent of patients required ICU stay. Twenty five patients received plasma therapy within 7 days (early) of diagnosis of Covid-19 infection. Median day of plasma infusion from date of diagnosis of Covid-19 infection was 4 days (range: 2-25 days). Patient who had early initiation of plasma therapy had shorter duration of hospitalisation (12.7 vs 24.3 days, p = 0.000). Overall mortality in the cohort was 45.5%. There was no effect of disease status, active therapy, presence of comorbidity on mortality. There was no difference in the mortality in patients receiving early vs late initiation of plasma therapy or in patients receiving one versus two plasma therapy. CONCLUSIONS We provide a large series of patients with hematological malignancies and role of CPT in this group.
Collapse
Affiliation(s)
- Preethi Jeyaraman
- Department of Hematology& Bone Marrow Transplantation, Max Superspecialty Hospital, Saket, New Delhi, 110017, India
| | | | | | | | - Rayaz Ahmed
- Rajiv Gandhi Cancer Institute, New Delhi, India
| | | | | | | | - Pronamee Borah
- Department of Hematology& Bone Marrow Transplantation, Max Superspecialty Hospital, Saket, New Delhi, 110017, India
| | - Rahul Naithani
- Department of Hematology& Bone Marrow Transplantation, Max Superspecialty Hospital, Saket, New Delhi, 110017, India.
| | | |
Collapse
|
4
|
Bansal A, Jeyaraman P, Gupta SK, Dayal N, Naithani R. Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation. Am J Blood Res 2020; 10:339-344. [PMID: 33489442 PMCID: PMC7811896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Accepted: 12/01/2020] [Indexed: 06/12/2023]
Abstract
BACKGROUND Infections are major contributor to morbidity and mortality in patients undergoing bone marrow transplant (BMT). OBJECTIVE To assess role of serum procalcitonin (PCT) as a useful biomarker for the infections and outcomes in these patients. METHODS Retrospective observational study. RESULTS Total 47 patients with febrile episodes were enrolled. Twenty patients underwent autologous BMT and 27 underwent allogeneic BMT. Bacterial infections were documented in 18/47 (38%) patients. Forty patients were neutropenic. The median fever duration was 10 days (range 3-30 days) in positive procalcitonin level group whereas it was 4 days (range 1-18) in negative group. This was statistically significant (P=0.000). Procalcitonin levels were high in 8/9 episodes of sepsis (P=0.029). Intensive care unit transfers and death were significantly higher in PCT positive group as compared to PCT negative group. CONCLUSION Serum procalcitonin levels provide prognostic information of worse outcome in patients undergoing HSCT.
Collapse
Affiliation(s)
- Amit Bansal
- Pharmaceutical Sciences and Research UniversityNew Delhi, India
| | - Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplant, Max Super-Speciality HospitalSaket, New Delhi, India
| | - S K Gupta
- Pharmaceutical Sciences and Research UniversityNew Delhi, India
| | - Nitin Dayal
- Department of Lab Medicine, Max Super-Speciality HospitalSaket, New Delhi, India
| | - Rahul Naithani
- Division of Hematology and Bone Marrow Transplant, Max Super-Speciality HospitalSaket, New Delhi, India
| |
Collapse
|
5
|
Borah P, Mirgh S, Sharma SK, Bansal S, Dixit A, Dolai TK, Lunkad S, Gupta N, Singh G, Jain A, Bansal D, Choudhary D, Khandelwal V, Doval D, Kumar M, Bhargava R, Chakrabarti A, Kalashetty M, Rauthan A, Kazi B, Mandal PK, Jeyaraman P, Naithani R. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis 2020; 87:102525. [PMID: 33338697 PMCID: PMC7723067 DOI: 10.1016/j.bcmd.2020.102525] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Accepted: 11/24/2020] [Indexed: 01/08/2023]
Abstract
BACKGROUND There is scarcity of data on outcome of COVID-19 in patients with hematological malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality. Secondary objectives were to correlate age, comorbidities and remission status with outcome. METHODS Retrospective multicentre observational study conducted in 11 centres across India. Total 130 patients with hematological malignancies and COVID-19 were enrolled. RESULTS Fever and cough were commonest presentation. Eleven percent patients were incidentally detected. Median age of our cohort was 49.5 years. Most of our patients had a lymphoid malignancy (n = 91). One-half patients (52%) had mild infection, while moderate and severe infections contributed to one-fourth each. Sixty seven patients (52%) needed oxygen For treatment of COVID-19 infection, half(n = 66) received antivirals. Median time to RT-PCR COVID-19 negativity was 17 days (7-49 days). Nearly three-fourth (n = 95) of our patients were on anticancer treatment at time of infection, of which nearly two-third (n = 59;64%) had a delay in chemotherapy. Overall, 20% (n = 26) patients succumbed. 14-day survival and 28-day survival for whole cohort was 85.4% and 80%, respectively. One patient succumbed outside the study period on day 39. Importantly, death rate at 1 month was 50% and 60% in relapse/refractory and severe disease cohorts, respectively. Elderly patients(age ≥ 60) (p = 0.009), and severe COVID-19 infection (p = 0.000) had a poor 14-day survival. The 28-day survival was significantly better for patients in remission (p = 0.04), non-severe infection (p = 0.00), and age < 60 years (p = 0.05). CONCLUSIONS Elderly patients with hematological malignancy and severe covid-19 have worst outcomes specially when disease is not in remission.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Naveen Gupta
- Mahatma Gandhi Medical College and Hospital, Jaipur, India
| | - Gurmeet Singh
- Jawahar Lal Nehru Hospital & Research Centre, Bhilai, India
| | | | | | | | | | - Divya Doval
- BLK Superspeciality Hospital, New Delhi, India
| | - Meet Kumar
- Fortis Memorial Hospital, Gurugram, India
| | | | | | | | | | - Bilal Kazi
- NRS Medical College and Hospital, Kolkata, India
| | | | | | | | | |
Collapse
|
6
|
Jeyaraman P, Borah P, Rajput P, Dayal N, Pathak S, Naithani R. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells Mol Dis 2020; 88:102464. [PMID: 32653327 DOI: 10.1016/j.bcmd.2020.102464] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 06/30/2020] [Accepted: 06/30/2020] [Indexed: 11/30/2022]
Abstract
Pure red cell aplasia is a known complication after ABO incompatible stem cell transplant. Due to rarity of disease, no established treatment guidelines are available for PRCA. Daratumumab is a monoclonal antibody against CD38 expressed by plasma cells. In this report we present our experience of successfully managing a patient of post-transplant PRCA with daratumumab. Our patient had failed multiple lines of therapy prior to receiving daratumumab. Response was seen after the 3rd weekly dose of daratumumab.
Collapse
Affiliation(s)
- Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplant, Max Super-speciality Hospital, India.
| | - Pronamee Borah
- Division of Hematology and Bone Marrow Transplant, Max Super-speciality Hospital, India
| | - Priyanka Rajput
- Division of Hematology and Bone Marrow Transplant, Max Super-speciality Hospital, India
| | - Nitin Dayal
- Department of Lab Medicine, Max Super-speciality Hospital, India
| | - Sangeeta Pathak
- Department of Transfusion Medicine, Max Super-speciality Hospital, India
| | - Rahul Naithani
- Division of Hematology and Bone Marrow Transplant, Max Super-speciality Hospital, India
| |
Collapse
|
7
|
Naithani R, Jeyaraman P, Mahapatra M. Alternative Strategies in Thalassemia: Focus on Thalidomide. Indian J Hematol Blood Transfus 2020; 36:227-228. [PMID: 32425370 PMCID: PMC7229089 DOI: 10.1007/s12288-020-01285-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
8
|
Jeyaraman P, Bhasin A, Dayal N, Pathak S, Naithani R. Daratumumab in dialysis-dependent multiple myeloma. Blood Res 2020; 55:65-67. [PMID: 32269978 PMCID: PMC7106121 DOI: 10.5045/br.2020.55.1.65] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 12/03/2019] [Accepted: 01/13/2020] [Indexed: 11/17/2022] Open
Affiliation(s)
- Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplant, Max Super-Specialty Hospital, New Delhi, India
| | - Alka Bhasin
- Department of Nephrology, Max Super-Specialty Hospital, New Delhi, India
| | - Nitin Dayal
- Department of Pathology, Max Super-Specialty Hospital, New Delhi, India
| | - Sangeeta Pathak
- Department of Transfusion Medicine, Max Super-Specialty Hospital, New Delhi, India
| | - Rahul Naithani
- Division of Hematology and Bone Marrow Transplant, Max Super-Specialty Hospital, New Delhi, India
| |
Collapse
|
9
|
Jeyaraman P, Borah P, Dayal N, Pathak S, Naithani R. Adequate Engraftment With Lower Hematopoietic Stem Cell Dose. Clin Lymphoma Myeloma Leuk 2020; 20:260-263. [PMID: 32019732 DOI: 10.1016/j.clml.2019.12.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Revised: 12/29/2019] [Accepted: 12/31/2019] [Indexed: 12/28/2022]
Abstract
BACKGROUND Adequate hematopoietic stem cell dose is required to proceed with autologous stem cell transplantation (ASCT). PATIENTS AND METHODS We conducted a retrospective analysis of 108 patients with multiple myeloma and lymphoma who underwent ASCT with noncryopreserved stem cells at our center. Data were compared for patients who received stem cell dose < 2 × 106/kg with those who received a higher dose. RESULTS The median CD34 dose collected in the lesser dose group was 1.76 × 106/kg (1.22 to 1.97 × 106/kg). Mean CD34 dose of the whole group was 4.96 ± 4.2 × 106/kg. Neutrophil engraftment was similar in both groups (12 vs. 11 days) (P = .065). Similarly, platelet engraftment occurred in 12 versus 11 days in both groups (P = .017). Length of hospital stay was similar in both groups. There was no significant difference in the incidence of proven bacterial infections between the 2 groups. There was no transplant-related mortality in lower dose group. CONCLUSION ASCT can be safely performed with lower hematopoietic stem cell dose in noncryopreserved setting.
Collapse
Affiliation(s)
- Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplantation, Max Super-specialty Hospital, Saket, New Delhi, India
| | - Pronamee Borah
- Division of Hematology and Bone Marrow Transplantation, Max Super-specialty Hospital, Saket, New Delhi, India
| | - Nitin Dayal
- Department of Lab Medicine, Max Super-specialty Hospital, Saket, New Delhi, India
| | - Sangeeta Pathak
- Department of Transfusion Medicine, Max Super-specialty Hospital, Saket, New Delhi, India
| | - Rahul Naithani
- Division of Hematology and Bone Marrow Transplantation, Max Super-specialty Hospital, Saket, New Delhi, India.
| |
Collapse
|
10
|
Jha SK, Borah P, Jeyaraman P, Jain A, Kumar D, Bal J, Naithani R. All That Lights-Up is not Lymphoma. Indian J Hematol Blood Transfus 2020; 36:213-214. [DOI: 10.1007/s12288-019-01185-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Accepted: 09/05/2019] [Indexed: 11/24/2022] Open
|
11
|
Naithani R, Jeyaraman P, Saikia B, Dayal N, Pathak S. Paroxysmal Cold Hemoglobinuria in a 4-year-old Child. Indian Pediatr 2019; 56:879-880. [PMID: 31724547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Paroxysmal Cold Hemoglobinuria is a rare cause of intravascular hemolysis presenting in children following an acute viral illness. It is usually self-limiting in nature. We present the details of a 4-year-old boy who presented with rapid onset intravascular hemolysis. Donath Landsteiner antibody test was positive and hemolysis resolved within two weeks of onset.
Collapse
Affiliation(s)
- Rahul Naithani
- Division of Hematology and Bone Marrow Transplantation, Max Superspeciality Hospital, Saket, New Delhi, India.
| | - Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplantation, Max Superspeciality Hospital, Saket, New Delhi, India
| | - Bhaskar Saikia
- Division of Pediatric Critical Care, Max Superspeciality Hospital, Saket, New Delhi, India
| | - Nitin Dayal
- Department of Laboratory Medicines, Max Superspeciality Hospital, Saket, New Delhi, India
| | - Sangeeta Pathak
- Department of Transfusion Medicine, Max Superspeciality Hospital, Saket, New Delhi, India
| |
Collapse
|
12
|
Sarkar J, Jeyaraman P, Naithani R. Hypercalcemia Related Pancreatitis in a Patient with Multiple Myeloma. Indian J Hematol Blood Transfus 2019; 36:200-201. [PMID: 32158107 DOI: 10.1007/s12288-019-01166-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Accepted: 07/25/2019] [Indexed: 12/23/2022] Open
Affiliation(s)
- Joyita Sarkar
- Division of Hematology and Bone Marrow Transplant, Max Superspeciality Hospital, Saket, New Delhi, Delhi India
| | - Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplant, Max Superspeciality Hospital, Saket, New Delhi, Delhi India
| | - Rahul Naithani
- Division of Hematology and Bone Marrow Transplant, Max Superspeciality Hospital, Saket, New Delhi, Delhi India
| |
Collapse
|
13
|
Jeyaraman P, Naithani R. Highlights of Abstracts on Hematopoietic Stem Cell Transplant in Annual Conference of ISHBT 2018. Indian J Hematol Blood Transfus 2019; 35:12-16. [PMID: 30828141 PMCID: PMC6369072 DOI: 10.1007/s12288-018-01067-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Accepted: 12/17/2018] [Indexed: 10/27/2022] Open
Abstract
Stem cell transplant in India has been seeing a steady progressive growth over the last decade. Thirty abstracts related to various aspects of bone marrow transplant were presented in the annual conference of Indian Society of Hematology and Transfusion medicine in 2018. All abstracts which were published were reviewed. They were categorized into autologous transplants, allogeneic transplants, lab aspects and supportive care. They have been summarized to provide a snapshot of the data presented. These data are likely to encourage to start or enhance transplant activity at other centers.
Collapse
Affiliation(s)
- Preethi Jeyaraman
- Division of Hematology and Bone Marrow Transplantation, Max Super Speciality Hospital, Saket, New Delhi, India
| | - Rahul Naithani
- Division of Hematology and Bone Marrow Transplantation, Max Super Speciality Hospital, Saket, New Delhi, India
| |
Collapse
|
14
|
Jeyaraman P, Jeyabala D, Meenarathi B, Tung KL, Anbarasan R. Synthesis, characterization, and drug release activity of structurally modified poly(vinyl alcohol). J Appl Polym Sci 2018. [DOI: 10.1002/app.46620] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Jeyaraman
- Department of Polymer Technology; Kamaraj College of Engineering and Technology; Virudhunagar Tamilnadu 626 001 India
| | - D. Jeyabala
- Department of Polymer Technology; Kamaraj College of Engineering and Technology; Virudhunagar Tamilnadu 626 001 India
| | - B. Meenarathi
- Department of Polymer Technology; Kamaraj College of Engineering and Technology; Virudhunagar Tamilnadu 626 001 India
| | - Kuo-Lun Tung
- Department of Chemical Engineering; National Taiwan University; Taipei Taiwan 10617 Republic of China
| | - R. Anbarasan
- Department of Chemical Engineering; National Taiwan University; Taipei Taiwan 10617 Republic of China
| |
Collapse
|
15
|
Rastogi P, Jeyaraman P, Sachdeva MU, Malhotra P, Ahluwalia J. Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature. Blood Res 2018; 53:160-163. [PMID: 29963523 PMCID: PMC6021561 DOI: 10.5045/br.2018.53.2.160] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2017] [Revised: 10/20/2017] [Accepted: 11/13/2017] [Indexed: 11/17/2022] Open
Affiliation(s)
- Pulkit Rastogi
- Department of Hematology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Preethi Jeyaraman
- Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Man Updesh Sachdeva
- Department of Hematology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Pankaj Malhotra
- Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| | - Jasmina Ahluwalia
- Department of Hematology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
| |
Collapse
|
16
|
Sahu KK, Sanamandra P, Jeyaraman P, Kumar G, Prakash G, Kumar N, Malhotra P. Unusual Cause of Cord Compression-A Pressing Issue for Neurosurgeons. World Neurosurg 2015. [PMID: 25963283 DOI: 10.1016/j.wneu.2015.04.061.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
Affiliation(s)
| | | | | | - Ganesh Kumar
- Department of Hematology, PGIMER, Chandigarh, India
| | - Gaurav Prakash
- Department of Internal Medicine, PGIMER, Chandigarh, India
| | | | | |
Collapse
|
17
|
Sahu KK, Sanamandra P, Jeyaraman P, Kumar G, Prakash G, Kumar N, Malhotra P. Unusual Cause of Cord Compression-A Pressing Issue for Neurosurgeons. World Neurosurg 2015; 92:565-567. [PMID: 25963283 DOI: 10.1016/j.wneu.2015.04.061] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 04/30/2015] [Indexed: 12/12/2022]
Affiliation(s)
| | | | | | - Ganesh Kumar
- Department of Hematology, PGIMER, Chandigarh, India
| | - Gaurav Prakash
- Department of Internal Medicine, PGIMER, Chandigarh, India
| | | | | |
Collapse
|
18
|
Samal SS, Jeyaraman P, Vishwakarma V. Sonochemical Coating of Ag-TiO<sub>2</sub> Nanoparticles on Textile Fabrics for Stain Repellency and Self-Cleaning- The Indian Scenario: A Review. ACTA ACUST UNITED AC 2010. [DOI: 10.4236/jmmce.2010.96036] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|